glp-1 agonist history Timeline of discovery and clinical development. (a) Key events in Safety and Tolerability of Glucagon-Like
Description
M., Janssen, I
That framework needs to be part of the prescription conversation, not an afterthought, and not something the patient discovers by searching online months into their treatment
Incidence of DR and NAION During the 2-year follow-up period, 5037 (2.7%) individuals in the GLP-1 RA group developed incident DR compared with 4938 (2.7%) individuals in the group without GLP-1 RA prescriptions (n = 185 066 per group
2009), while DURATION-6 showed substantial decreases in both HbA1c and weight with liraglutide relative to weekly exenatide (Drucker et al
Will my weight return after stopping Trulicity
